Overhead view of a doctor looking at his clipboard

Pipeline

Aldeyra Is a Well-Capitalized Biotechonology Company with a Broad Immunology Pipeline

Product CandidatesDisease TargetsPreclinicalPhase 1Phase 2Phase 3NDA Review

Reproxalap

Disease Targets: Dry Eye Disease

Type (ophthalmic solution) Option agreement w/AbbVie

Dry Eye Disease
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review

Reproxalap

Disease Targets: Allergic Conjunctivitis

Type (ophthalmic solution) Option agreement w/AbbVie

Allergic Conjunctivitis
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review

ADX-629

Disease Targets: Moderate Alcoholic Hepatitis

Type (oral administration)

Moderate Alcoholic Hepatitis
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review

ADX-629

Disease Targets: Sjögren-Larsson Syndrome

Type (oral administration)

Sjögren-Larsson Syndrome
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review

ADX-246

Disease Targets: Atopic Dermatitis

Type (oral administration)

Atopic Dermatitis
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review

ADX-246

Disease Targets: Metabolic Disease

Type (oral administration)

Metabolic Disease
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review

ADX-248

Disease Targets: Dry Age-Related Macular Degeneration / Geographical Atrophy

Type (intravitreal injection)

Dry Age-Related Macular Degeneration / Geographical Atrophy
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review

ADX-2191*

Disease Targets: Retinitis Pigmentosa

Type (intravitreal injection)

Retinitis Pigmentosa
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review

*U.S. FDA Orphan-Drug Designated